Cargando…

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Fatty acid synthase (FASN) is an attractive therapeutic target in non-alcoholic steatohepatitis (NASH) because it drives de novo lipogenesis and mediates pro-inflammatory and fibrogenic signaling. We therefore tested pharmacological inhibition of FASN in human cell culture and in three diet induced...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Farrell, Marie, Duke, Greg, Crowley, Richard, Buckley, Douglas, Martins, Eduardo B., Bhattacharya, Dipankar, Friedman, Scott L., Kemble, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485253/ https://www.ncbi.nlm.nih.gov/pubmed/36123383 http://dx.doi.org/10.1038/s41598-022-19459-z

Ejemplares similares

FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression
por: Heuer, Timothy S., et al.
Publicado: (2016)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
por: Huisman, Tsipora M, et al.
Publicado: (2021)

Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
por: Peverill, William, et al.
Publicado: (2014)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales
por: Carter, James K., et al.
Publicado: (2021)

Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH
por: Tan, Mingjun, et al.
Publicado: (2020)

MicroRNA Expression Relating to Dietary-Induced Liver Steatosis and NASH
por: Zarfeshani, Aida, et al.
Publicado: (2015)

Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis
por: Shepherd, Emma L., et al.
Publicado: (2020)

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells
por: Schroeder, Barbara, et al.
Publicado: (2021)

Identification of Acetylation Sites of Fatty Acid Synthase (FASN) by Mass Spectrometry and FASN Activity Assay
por: Miao, Ting, et al.
Publicado: (2023)

Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models
por: Bhattacharjee, Jashdeep, et al.
Publicado: (2023)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH
por: Montefusco, David, et al.
Publicado: (2022)

Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling
por: Xie, Yang, et al.
Publicado: (2023)

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013)

BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018)

Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs
por: Duvivier, Valérie, et al.
Publicado: (2022)

The fasn-1(g14ts) allele is a Gly1830Arg missense mutation in C. elegans FASN-1
por: Bai, Xiaofei, et al.
Publicado: (2020)

MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN
por: Fan, Jiahui, et al.
Publicado: (2017)

MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

The effect of cocoa supplementation on hepatic steatosis, reactive oxygen species and LFABP in a rat model of NASH
por: Janevski, Mile, et al.
Publicado: (2011)

Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC
por: Ribas, Vicent, et al.
Publicado: (2021)

LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH
por: Takata, Noboru, et al.
Publicado: (2021)

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
por: van Koppen, Arianne, et al.
Publicado: (2017)

FASN activity is important for the initial stages of the induction of senescence
por: Fafián-Labora, Juan, et al.
Publicado: (2019)

Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
por: Kang, Gideon G., et al.
Publicado: (2022)

Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
por: Li, Xinlei, et al.
Publicado: (2023)

Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH)
por: Wu, Jiayu, et al.
Publicado: (2018)

Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress
por: Palladini, Giuseppina, et al.
Publicado: (2019)

Hepatic Stellate Cell-Immune Interactions in NASH
por: Carter, James K., et al.
Publicado: (2022)

Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis
por: Vijayakumar, Archana, et al.
Publicado: (2022)

CD4(+) T cell activation and inflammation in NASH-related fibrosis
por: Zhou, Yunfeng, et al.
Publicado: (2022)

MAPK/P53-mediated FASN expression in bone tumors
por: Jiang, Ye, et al.
Publicado: (2017)

Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma
por: Sun, Tianhao, et al.
Publicado: (2019)

FASN-dependent de novo lipogenesis is required for brain development
por: Gonzalez-Bohorquez, Daniel, et al.
Publicado: (2022)

A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer
por: Yang, Li, et al.
Publicado: (2016)

Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using (1)H-MRS
por: Xavier, Aline, et al.
Publicado: (2019)

Hepatic Fibrosis and Steatosis in Metabolic Syndrome
por: Gangireddy, Venu Gopala Reddy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p131vs8f5s84bknflbeamoanfn